Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

NCT06016842 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06016842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06016842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2023
Completion date
May 31, 2029
Enrollment
276 (estimated)
Sites
198

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis (pbc)